



PRESS RELEASE

Michael Oredsson becomes CEO of A-Mansia Biotech, the company exploiting the discovery of *Akkermansia muciniphila*

Mont-Saint-Guibert, 18th March 2021 - Michael Oredsson has been appointed CEO of the Belgian biotech company A-Mansia, to lead the company in its upcoming commercial phase. He succeeds Jean-Christophe Malrieu, who has been at the head of the company since its foundation. A-Mansia is developing a new generation of microbiome health products based on the commensal bacterial species *Akkermansia muciniphila*, targeting type II diabetes and obesity.

Michael has 30 years' experience in senior roles in Life Science and FMCG, including more than 20 years as CEO in listed and private companies. During that period, he also served as chairman and held board positions in a number of life science companies.

Before joining A-Mansia, Michael held notable positions as CEO of probiotics company Probi and biotech company BioInvent, both listed on Nasdaq Stockholm. He is a native of Sweden but has worked internationally throughout his career. As such, he is uniquely qualified to lead A-Mansia in the next phase of its growth as the company prepares for commercialization of its *Akkermansia*-based products.

"In view of the excellent progress of A-Mansia, we expect that products based on *Akkermansia muciniphila* will create a paradigm shift in microbiome health. I am very excited to take up the CEO role and to join the team in Belgium to deliver on these expectations and take the company to the next phase," says Michael Oredsson.

"With his impressive track record in probiotics and biotechnology and his international experience, Michael Oredsson brings valuable expertise and knowledge to the company. His appointment as CEO will help A-Mansia to realise its potential and progress towards the launch of our first product", says Cees de Jong, Chairman of the board at A-Mansia.

"The whole Board of Directors joins me in thanking Jean-Christophe Malrieu for his dedication in building the company, leading the successful development of products, and preparing for the upcoming phase of market introduction.", concludes Cees de Jong.



A-Mansia
BIOTECH

About A-Mansia Biotech

Founded in 2016, A-Mansia Biotech SA is a Belgium-based microbiome start-up working on discoveries made by its founding scientists, Professor Willem M. de Vos, from Wageningen University, The Netherlands and Professor Patrice D. Cani, from the University of Louvain (UCLouvain), Belgium. Its R&D is conducted in collaboration with the laboratories of UCLouvain and Wageningen University. A-Mansia is developing health products based on the unique properties of the *Akkermansia muciniphila* commensal bacterial species. The Company has secured €18m series A financing led by Seventure Partners together with Innovation Industries, Fonds Vives II (UCLouvain), the SRIW and Mr Pierre Drion, and is supported by a large non-dilutive grant from the Walloon regional government.

Press contact

Florence Muls – Interel Belgium
Florence.muls@interelgroup.com
+ 32 (0)486 410 805